// App-Quantinova.ai

FP07.05 : DREAM3R: Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

Researchers

Presenter

  • P. Forde

Principal Investigators

  • C. Brown

  • Z. Sun

  • S. Yip

  • V. Anagnostou

  • A. Cook

  • H. Kindler

  • A. Tsao

  • M. Zauderer

  • K. Fitzpatrick

  • K. Ford

  • N. Pavlakis

  • S. Ramalingam

  • A. Nowak

Medical Centers

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  • Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore/US

  • Univesity of Chicago, Chicago, USA

  • Emory University, Atlanta, GA

  • Memorial Sloan Kettering Cancer Institute,New Yor

  • National Centre for Asbestos Related Diseases and Medical School, University of Western Australia, Perth/WA/AU

  • Ibcsg Statistical Center, Boston/US

  • Precog, Philadelphia/PA/US

  • Genesis Care (Formerly Northern Cancer Institute), Sydney/NSW/AU

  • National Centre for Asbestos Related Diseases, Medical School of University of Western Australia and Sir Charles Gairdner Hospital, Perth/WA/AU

  • National Centre for Asbestos Related Diseases, University of Western Australia, Nedlands, Australia

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Princess Alexandra Hospital & Queensland University of Technology, Brisbane, Australia

  • 4Nhmrc Clinical Trials Centre, the University of Sydney, Camperdown/NSW/AU

  • The Prince Charles Hospital, Cancer Care Services, and University of Queensland, Brisbane/AU

Locations

  • United States

  • United Kingdom

  • Canada

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Malignant pleural mesothelioma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Durvalumab

  • Pemetrexed

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT04334759

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved